Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of RAS(ON) Inhibitors in RAS-Mutated NSCLC and Solid Tumors
NCT06162221Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 13
01
Overview
Phase 2, open-label trial of elironrasib, daraxonrasib and zoldonrasib in non-small cell lung cancer (NSCLC) and solid tumor (4 arms), sponsored by Revolution Medicines. Primary endpoints: Adverse events at 5 years and Dose limiting toxicities at 21 days. Started Jan 2024; status: recruiting.
02
Drugs
elironrasibdaraxonrasibzoldonrasib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06162221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162221.